Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- Check3 days agoChange DetectedRemoved related topics tags: 'Type 2 diabetes' and 'MedlinePlus Genetics' from the study page.SummaryDifference0.2%

- Check10 days agoChange DetectedRevision label updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThe page now shows Revision: v3.4.2; the prior government-funding lapse notice and the Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check45 days agoChange DetectedNotice: Added a government funding lapse banner and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check52 days agoChange DetectedAdded a 'Show glossary' option and updated footer labels to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', along with the site revision updated to v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

- Check66 days agoChange DetectedThe page metadata was updated: 'Type 2 diabetes' added with related topic 'MedlinePlus Genetics', and the page revision updated from v3.3.3 to v3.3.4.SummaryDifference0.2%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.